

Sarcomatoid Dedifferentiated Melanoma arising in a melanoma-in situ

Pennsylvania Academy of Dermatology and Dermatologic Surgery

9/23/2023

Megan O'Donnell-Cappelli, MD - PGY3

Thomas Jefferson University Hospital, Department of Dermatology and Cutaneous Biology

HOME OF SIDNEY KIMMEL MEDICAL COLLEGE


1

Clinical History


A 78-year-old man with a history of numerous non-melanoma skin cancers and melanoma in-situ presented with a 2 month history of an ulcerating papule on the cheek at the edge of his previous melanoma in-situ excision scar that was diagnosed and treated five years prior.




2




3



4



5



6

Molecular analysis - next generation sequencing

NF1, CDKN2A, TP53, and TSC1 mutations
detected in the spindle cell component

7


Pathology

Diagnosis: Malignant Spindle Cell Neoplasm, Ulcerated and Melanoma In-Situ

Consistent with sarcomatoid dedifferentiated melanoma arising in a melanoma in-situ


8

Treatment: Mohs micrographic surgery




10


Pathology: permanent section of Mohs surgery debulk



11



13



14

Treatment and Outcome

- Sentinel lymph node biopsy: negative
- PET scan: negative

17

Proposed diagnostic criteria for dedifferentiated/undifferentiated melanomas

TABLE 5 - Criteria Proposed to Diagnose Undifferentiated Metastatic Malignant Melanoma

Histologically and/or immunohistochemically proven primary cutaneous or mucosal melanoma

OR

At least 1 histologically and/or immunohistochemically proven differentiated melanoma MUP

Exploration of the remote clinical history (primary tumor might have been excised decades ago)

Review of previously excised melanocytic lesion/s to exclude melanoma before adopting a diagnosis of MUP

Undifferentiated histology in the metastasis (UPS) with multiple cytologic (epithelioid, rhabdoid, spindled and pleomorphic cells) patterns

Inconclusive immunophenotyping with either vimentin-only immunophenotype or phenotypes/patterns of limited specificity, eg, pleomorphic rhabdomyoblastic, smooth muscle-like, myofibroblast-like, osteocartilaginous, primitive small cell or multiple patterns

Lack of histologic patterns that are known to be associated with specific or defining genetic alterations/etiology such as synovial sarcoma, EWSR1-positive Ewing sarcoma, conventional leiomyosarcoma, etc.

Undifferentiated metastasis not epicentered at a site of previous irradiation (otherwise postradiation sarcoma should be considered)

Demonstration of a melanoma-compatible or melanoma-typical genotype or of a mutation known to have occurred in the primary melanoma, eg, *BRAF*, *NRAS*, *KIT*, or *NF1* mutation*

In the very exceptional cases with frankly epithelial differentiation, eg, adenocarcinoma-like, exclude another primary, eg, *BRAF* mutated colorectal carcinoma, etc. by appropriate clinical examination/imaging

Exclude undifferentiated neoplasms with possible *BRAF* mutation such as anaplastic thyroid carcinoma by appropriate immunohistochemistry and/or clinical examination/imaging

Our patient

18

Sarcomatoid Dedifferentiated Melanoma (SDDM)

- Rare aggressive spindle cell subtype of melanoma that simulates a sarcoma
- Clinical presentation:
 - Large, thick hemorrhagic and ulcerated nodule
 - Usually diagnosed at late stage with significant depth or once already metastasized
- All reported cases show a biphasic morphology: conventional melanoma + pleomorphic spindle cell component
- Diagnostic challenge:
 - Absence of specific clinical features
 - Spindle cells lack expression of the usual melanocytic markers including S100, SOX10, MITF, and Melan A
 - Stains diffusely for CD10 - can mimic atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS)

Next Generation Sequencing (NGS)

- Mutational profiling through NGS assays can help to establish the correct diagnosis when staining is ambiguous
- Mutational analysis by NGS on cases of SDDM can be performed on microdissected sections of the sarcomatoid and conventional melanoma components.

TABLE 1. - Summary of Shared Mutations Between Conventional Melanoma and the Sarcomatoid Component in Cases of SDDM Described in the Literature (Adapted From Chung et al⁷)

Author and year	Age/Sex	Site/Clinical Information	Breslow Depth/Stage	Shared Mutation
Kiuri et al (2014) ¹	66/M	Scalp hemorrhagic nodule	Not provided	† TP53 —p.R248Q, p.P219L, p.V147A CDKN2A —p.E26 * TSC2 —p.G1367S NF1 —p.R2179C *
Erstine et al (2017) ²	65/F	Right inframammary 1.8 cm polypoid ulcerated lesion	9 mm, Stage III	BRAF —wild type
	62/M	Left heel ulcerated pedunculated mass	4.5 mm, Stage III	BRAF —wild type NRAS —wild type KIT —wild type
Lefferts et al (2020) ³	73/M	Left thigh 6 × 5 × 3 cm pedunculated nodule	7.9 mm, Stage III	TP53 —p.P278S NRAS —p.Q61L
Chung et al (2021) ⁵	72/M	Left cheek ulcerated nodule	1.8 mm, Stage IIA	§ TP53 CDKN2A TSC1 *
Agaimy et al (2021) ⁴	74/M	Lower rectum lesion	Not provided	¶ KIT —p.L576P
Current case*‡	65/M	Right medial knee crusted nodule	3.3 mm, Stage IIIC	TP53 —p.R213 NRAS —p.Q61K TERT —c.-139_138delinsTT JAK2 —p.V617F

21

Conclusions

- SDDM is a rare diagnosis and serves as a diagnostic challenge as it lacks characteristic melanocytic staining
- Recognition of an associated conventional melanoma is an essential clue in diagnosis of SDDM
- Molecular mutational analysis can aid in accurate diagnosis
- Can consider Moh's micrographic surgery as treatment

23

References

- 1- Erstine EM et al., *Am J Dermatopathol.* 2017 Aug;39(8):593-598.
- 2- Lefferts JA et al., *J Cutan Pathol.* 2020 Jun;47(6):541-547.
- 3- Kiuru M et al., *Am J Surg Pathol.* 2014 Jun;38(6):864-70.
- 4- Chung J et al., *J Cutan Pathol.* 2021 Jul;48(7):943-947.
- 5- Valiga AA et al., *Am J Dermatopathol.* 2022 Apr 1;44(4):282-286.
- 6- Kooper-Johnson S et al., *Am J Dermatopathol.* 2020 Sep;42(9):697-699
- 7- Fraga GR et al., *Am J Dermatopathol.* 2018 Apr;40(4):304-305.
- 8- Massey RA et al., *Dermatol Surg.* 1998 Sep;24(9):995-8.